TOVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Theriva Biologics Inc (TOVX) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks positive momentum, has weak financial performance, and no significant catalysts to drive growth in the near term. While analysts have upgraded the stock with a $1 price target, the current pre-market price of $0.2431 reflects significant downside risk. The lack of trading trends, no recent news, and no proprietary trading signals further suggest holding off on this investment for now.
The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 59.497, indicating no overbought or oversold conditions. The stock is trading near its pivot level of $0.241, with resistance at $0.29 and support at $0.191. Overall, the technical indicators do not suggest a strong buy signal.
Analysts have upgraded the stock to Buy with a $1 price target, citing potential progress in the VCN-01 program for pancreatic cancer.
Pre-market price is down 5.48%, reflecting negative sentiment. Financial performance is weak, with declining net income (-21.16% YoY) and EPS (-92.45% YoY). No recent news or significant trading activity from insiders or hedge funds.
In Q4 2025, revenue remained at $0 with no growth. Net income dropped to -$3,506,000 (-21.16% YoY), and EPS fell to -0.12 (-92.45% YoY). Gross margin remained at 0%. The financials indicate poor performance and lack of growth.
Maxim upgraded the stock to Buy with a $1 price target, citing potential for progress in the VCN-01 program. Alliance Global lowered its price target from $7 to $4 due to an increased share count but maintained a Buy rating.
